Tarsus Funding: How Much Did They Raise & Key Investors

How Much Did Tarsus Raise?
Funding & Key Investors

Tarsus Pharmaceuticals has solidified its position within the competitive biopharmaceutical landscape, securing a total funding amount of $235M to advance its clinical-stage pipeline. This capital infusion, highlighted by a recent funding amount of $175M, underscores the market confidence in the company's specialized approach to ophthalmic therapeutics. By maintaining a robust balance sheet, Tarsus is well-positioned to navigate the complexities of late-stage drug development and commercialization, ensuring that its proprietary solutions for underserved ocular conditions reach the clinical market with precision and scale.

The company's growth trajectory, marked by a series of strategic financing rounds, reflects a disciplined approach to capital allocation. From its early-stage development to its current status as a major enterprise-level entity, Tarsus has consistently attracted high-caliber institutional backing. This financial foundation is critical as the firm transitions from research-heavy operations to a more commercial-centric model, aiming to address significant unmet medical needs in the ophthalmology sector.

What is Tarsus?

Tarsus

Manufacturing

Pharmaceuticals

Business Services

Founded in 2017 and headquartered in Irvine, California, Tarsus Pharmaceuticals operates as a clinical-stage biopharmaceutical firm dedicated to the development of novel therapies for a variety of diseases. The company's primary focus is the advancement of a topical ophthalmic product designed to target the underlying causes of blepharitis, a common yet often undertreated ocular condition. By leveraging innovative pharmacological pathways, Tarsus aims to disrupt the standard of care in ophthalmology, positioning itself as a leader in the development of targeted, patient-centric treatments. The company's operational strategy integrates rigorous clinical validation with a clear commercial roadmap, allowing it to maintain a competitive edge in the highly regulated life sciences industry.

How much funding has Tarsus raised?

Tarsus has raised a total of $360M across 2 funding rounds:

2020

Series B

$60M

2022

Debt

$175M

Series B (2020): $60M with participation from Vivo Capital, Horowitz Group, Flying L Partners, APERTURE Venture Partners, Frazier Healthcare Partners, and Visionary Ventures

Debt (2022): $175M, investors not publicly disclosed

Key Investors in Tarsus

Vivo Capital

A global healthcare investment firm founded in 1996 that manages private and public equity alongside venture capital to support life sciences innovation.

APERTURE Venture Partners

A specialized healthcare investment firm focused on collaborating with entrepreneurs to develop innovative companies in the medical device, pharmaceutical, and diagnostic sectors.

Visionary Ventures

An Orange County-based venture capital firm that leverages an information advantage strategy and partnerships with industry experts to fund promising life sciences and ophthalmology startups.

What's next for Tarsus?

Looking ahead, Tarsus Pharmaceuticals is poised to leverage its recent capital injection to accelerate its clinical programs and expand its therapeutic footprint. The strategic focus remains on the successful commercialization of its lead ophthalmic candidate, which represents a significant opportunity to capture market share in the ocular health space. As the company matures, investors will likely monitor the progress of its regulatory filings and the scalability of its distribution infrastructure. With a strong backing from specialized healthcare venture firms, Tarsus is well-equipped to navigate the challenges of the biopharmaceutical market, potentially setting the stage for long-term value creation and sustained innovation in the treatment of chronic eye diseases.

See full Tarsus company page

See More Financial Insights